Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma
The Journal of Dermatology Feb 08, 2018
Yamazaki N, et al. - The safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of dabrafenib (150 mg BID) plus trametinib (2 mg QD) in Japanese patients with BRAF V600E/K mutant solid tumors (phase 1) and melanoma (phase 2) were determined. The data revealed that the plasma concentrations of dabrafenib and trametinib reached a steady state by week 3. Hence, the efficacy and PK properties of the dabrafenib+trametinib combination in Japanese patients were shown to be comparable with those noted in global studies.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries